Company

Dave Zhang is the CEO at NuProbe USA. Dave co-founded NuProbe in 2016, and is the inventor of many of NuProbe’s technologies. Previously, he was a tenured professor of Bioengineering at Rice University. He was awarded the Presidential Early Career Award in Science and Engineering (PECASE) in 2019, the highest honor for early-career scientists in the US. Dave is also a co-founder and board member of Torus Biosystems.

Nicolas Garreau de Loubresse, PhD, serves as Director of Business Development & Service for NuProbe, USA. Previously, he was a Research Fellow at the Wyss Institute at Harvard University and a Business Development Fellow at Harvard Office of Technology Development. He is also the co-founder of Urania Therapeutics and inventor of Urania’s core technologies. He published first-author articles in Science and Nature, and received competitive fellowships (EMBO, HFSP) and awards (AXA-French Academy of Science).

Janet Huang, MBA is currently the Director of Operations of NuProbe, USA. She has more than 5 years’ work experience in finance, operation, accounting and supply chain management. She received her MBA degree from University of Houston-Downtown and a Bachelor’s degree with triple major in accounting, human resource management and general management from Baylor University. Ms. Janet founded her own company in 2015 and achieved 1 Million sales revenue in RMB in just one year. She sold her company in 2018.

Yalei Wu is the Director of R&D, Bioinformatics at NuProbe USA. He brings with him 10+ years of biotech-industry experience. His interest is to apply bioinformatics to improving assay design, information extraction and ultimately contributing to better human health. His research is published in top scientific journals such as Nature Biomedical Engineering, Science, and PNAS. He holds numerous patents in algorithm and NGS methods. Prior to joining NuProbe, he was VP of R&D at XGEN and Associate Director at ThermoFisher Scientific.

Jinny Zhang is the Associate Director of Innovation at NuProbe. She received her PhD in Systems, Synthetic and Physical Biology from Rice University, Houston.

George M. Church, PhD, is a Professor of Genetics at Harvard Medical School, a Professor of Health Sciences and Technology at Harvard and MIT, and a Founding Member of the Wyss Institute for Biologically Inspired Engineering at Harvard. Dr. Church is also Director of the U.S. Department of Energy Technology Center, Director of the National Institutes of Health Center of Excellence in Genomic Science, and Director of the Personal Genome Project. He is the co-founder of more than 15 biotech companies including AbVitro, Editas Medicine, Veritas Genetics, Warpdrive Bio, eGenesis and ReadCoor. He is a member of the National Academy of Sciences, the National Academy of Engineering and the Franklin Bower Laureate for Achievement in Science. He received a B.A. in Zoology and Chemistry from Duke University and a Ph.D. in Biochemistry and Molecular Biology from Harvard University.

David R. Walt, PhD, is a member of the faculty at Harvard Medical School in the Department of Pathology at Brigham and Women’s Hospital, is a Member of the Wyss Institute, and is a Howard Hughes Medical Institute Professor. Previously, he was University Professor at Tufts University. Dr. Walt is the Scientific Founder of Illumina and Quanterix and has co-founded several other life sciences startups including Ultivue and Arbor Biotechnologies. He is a member of the National Academy of Engineering, the National Academy of Medicine, a Fellow of the American Academy of Arts and Sciences, a Fellow of the American Institute for Medical and Biological Engineering, and a Fellow of the National Academy of Inventors. He received a B.S. in Chemistry from the University of Michigan and a Ph.D. in Chemical Biology from SUNY at Stony Brook.

Amir A. Jazaeri, MD is currently the Vice Chair for Clinical Research and the Director of the Gynecologic Cancer Immunotherapy Program in the Department of Gynecologic Oncology and Reproductive Medicine at MD Anderson. He is the principal investigator for several sponsored and investigator-initiated clinical trials. He received his B.S. and M.D. from the University of Virginia and completed his residency in Obstetrics and Gynecology there. He finished his fellowship in Gynecologic Oncology at the National Cancer Institute and MD Anderson Cancer Center.

Abhijit Patel, MD, PhD is an Associate Professor of Therapeutic Radiology at Yale University. He is a physician-scientist with an active clinical practice in radiation oncology and with scientific expertise in nucleic acid biochemistry. His research lab at Yale is working to develop and clinically validate noninvasive DNA-based cancer diagnostics, with a particular focus on the assessment of therapeutic efficacy and early cancer detection.  He received his Ph.D. in Molecular Biophysics and Biochemistry, and M.D. from Yale University.